Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial

CONCLUSIONS AND RELEVANCE: These findings suggest that anti-EGFR rechallenge therapy has promising antitumor activity in patients with refractory ctDNA RAS/BRAF wt mCRC. Within the limitation of a subgroup analysis, the absence of liver metastases was associated with significant improved survival.TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT02296203; NCT04561336; NCT03227926; NCT05468892.PMID:38592721 | DOI:10.1001/jamanetworkopen.2024.5635

Source: Cancer Control - April 9, 2024 Category: Cancer & Oncology Authors: Davide Ciardiello Erika Martinelli Teresa Troiani Gianluca Mauri Daniele Rossini Giulia Martini Stefania Napolitano Vincenzo Famiglietti Sara Del Tufo Gianluca Masi Daniele Santini Antonio Avallone Filippo Pietrantonio Sara Lonardi Massimo Di Maio Maria G Source Type: research